IN HUMAN LIVER MICROSOMES, ABACAVIR DID NOT INHIBIT CYTOCHROME P450 ISOFORMS (2C9, 2D6, 3A4). BASED ON THESE DATA, IT IS UNLIKELY THAT CLINICALLY SIGNIFICANT DRUG INTERACTIONS WILL OCCUR BETWEEN ABACAVIR AND DRUGS METABOLIZED THROUGH THESE PATHWAYS.
CHANCES OF LACTIC ACIDOSIS INCREASES ON COADMINISTRATION WITH RIBAVERIN WHICH HAS SIMILAR MECHANISM OF ACTION.